Claimed effect · Orforglipron

Does Orforglipron help with body weight?

A
Grade A — established in humansPhase 3 RCT (n=3,127) + programme · effect size: moderate
Short answerEstablished in humans. Phase 3 RCT (n=3,127) + programme point the same way: a moderate effect. ATTAIN-1, 72 weeks in adults with obesity and no diabetes: −11.2% on the 36 mg dose versus −2.1% on placebo. 36.0% lost at least 15% of body weight, against 5.9% on placebo.

What the studies show

ATTAIN-1, 72 weeks in adults with obesity and no diabetes: −11.2% on the 36 mg dose versus −2.1% on placebo. 36.0% lost at least 15% of body weight, against 5.9% on placebo.

“The mean change in body weight from baseline to week 72 was -7.5% (95% confidence interval [CI], -8.2 to -6.8) with 6 mg of orforglipron, -8.4% (95% CI, -9.1 to -7.7) with 12 mg of orforglipron, and -11.2% (95% CI, -12.0 to -10.4) with 36 mg of orforglipron, as compared with -2.1% (95% CI, -2.8 to -1.4) with placebo (P<0.001 for all comparisons with placebo).”

Verbatim, from the abstractWharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med, 2025;393:1796–1806

Several well-run randomised trials in people, pointing the same way. You can plan around this. It still says nothing about whether the effect is worth the side effects for you.

  1. 1

In context

Orforglipron (Foundayo) is a once-daily tablet that activates the GLP-1 receptor. It is not a peptide — it is a small molecule, which is why it survives digestion and needs no injection, refrigeration or food restriction. Its phase 3 programme is published: about 11% average weight loss over 72 weeks in obesity, and HbA1c reductions of roughly 1.5 points in early type 2 diabetes. The FDA approved it for weight management on 1 April 2026. The effect is smaller than injected tirzepatide or semaglutide; the delivery is far easier.

Orforglipron is approved (rx) — united states. Legal status differs by country — see the regulation section or the jurisdiction pages.

Questions

Is Orforglipron proven to help with body weight?
Yes, as far as human trials can show it: Phase 3 RCT (n=3,127) + programme. LYO grades this outcome A.
What studies are behind the grade?
ATTAIN-1, 72 weeks in adults with obesity and no diabetes: −11.2% on the 36 mg dose versus −2.1% on placebo. 36.0% lost at least 15% of body weight, against 5.9% on placebo.
Is Orforglipron approved for this?
Orforglipron is an approved medicine (Approved (Rx) — United States); whether this particular outcome is a licensed indication is stated on the compound page's regulation section.

Other outcomes for Orforglipron

Written and maintained by LYO Research — how pages are written and checked. Reviewed 7 October 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →